Pfizer's Lyrica gets European approval for nerve pain

By Angela McDaniels

Seattle, Sept. 18 - Pfizer Inc. said the European Commission granted approval to Lyrica (pregabalin capsules) for the treatment of central neuropathic pain.

This approval broadened the range of neuropathic pain that Lyrica is approved to treat in Europe to include nerve pain associated with conditions such as spinal cord injury, stroke and multiple sclerosis, according to a company news release.

In the United States, Lyrica is approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia and for the adjunctive treatment of partial onset seizures in adults.

Pfizer, a New York-based pharmaceutical company, said the drug is believed to work by calming hyper-excited neurons, which may be an underlying cause for various types of nerve pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.